Financial Analysis: Appili Therapeutics (OTCMKTS:APLIF) vs. Dare Bioscience (NASDAQ:DARE)

Appili Therapeutics (OTCMKTS:APLIF) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Appili Therapeutics and Dare Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Appili Therapeutics	0	0	0	0	0.00
Dare Bioscience	1	0	2	0	2.33

Dare Bioscience has a consensus target price of $10.00, suggesting a potential upside of 455.25%. Given Dare Bioscience’s stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Appili Therapeutics.

Valuation & Earnings

This table compares Appili Therapeutics and Dare Bioscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Appili Therapeutics	$70,000.00	21.18	-$1.89 million	($0.03)	-0.37
Dare Bioscience	$1.03 million	25.46	-$13.40 million	($1.25)	-1.44

Appili Therapeutics has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Appili Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Appili Therapeutics has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Profitability

This table compares Appili Therapeutics and Dare Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Appili Therapeutics	N/A	N/A	-190.26%
Dare Bioscience	N/A	N/A	-56.52%

Institutional & Insider Ownership

6.7% of Dare Bioscience shares are held by institutional investors. 11.8% of Appili Therapeutics shares are held by company insiders. Comparatively, 4.8% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Dare Bioscience beats Appili Therapeutics on 8 of the 12 factors compared between the two stocks.

About Appili Therapeutics

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

About Dare Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.